New treatment options for bladder cancer patients: based on ASCO 2022 materials and beyond
-
Published:2022-10-01
Issue:3
Volume:10
Page:151-155
-
ISSN:2308-6424
-
Container-title:Urology Herald
-
language:
-
Short-container-title:Vestn. Urol.
Author:
Zyatchin I. V.1ORCID, Reva S. A.2ORCID
Affiliation:
1. Pavlov First Saint-Petersburg State Medical University (Pavlov University) 2. Pavlov First Saint-Petersburg State Medical University (Pavlov University); Petrov National Medical Research Center of Oncology
Abstract
Bladder cancer is the fourth most common cancer worldwide and the eighth leading cause of cancer mortality in men. The advent of new systemic therapies, including PD-1 and PD-L1 inhibitors, and advances in biomarker development have revolutionized the treatment of this disease. The current guidelines of the National Comprehensive Cancer Network (NCCN) support the inclusion of some new therapies in clinical practice. Over the past decade, many approvals for immuno-therapeutic agents have been obtained. Since bladder cancer is characterized by a high frequency of mutations, there has been a widespread introduction of medicines from the group of immune checkpoint inhibitors. All studies from this review were presented at a recent meeting of the American Society of Clinical Oncology (ASCO) and published in reputable journals.
Publisher
Rostov State Medical University
Reference9 articles.
1. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866-878. https://doi.org/10.6004/jnccn.2022.0041 2. Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. 2020;203(5):902-909. https://doi.org/10.1097/JU.0000000000000688 3. Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919-930. https://doi.org/10.1016/S1470-2045(21)00147-9 4. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. https://doi.org/10.1056/NEJMoa2034442 5. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://doi.org/10.1056/NEJMoa2002788
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|